ERBB2 and neoplasm: As these changes mostly concerned recurrences of HER2-negative and HER2-low tumours, we compared main clinical and pathological characteristics of primary HER2-negative BCs, stratified by the HER2 status evolution category (stable or changed status)—it is the first time such a study has ever been reported in the literature.